麦丽谊,陈昕,安金蒙,蒋杰
MAI Liyi,CHEN Xin,AN Jinmeng,JIANG Jie

• 1:东莞暨南大学研究院

摘要(Abstract)：

目的为我国仿制药进入美国市场提供参考。方法通过文献分析和例证法等方法,阐述美国ANDA(Abbreviate New Drug Application,简略新药申请)审评中的审评程序、技术要求及常见缺陷。结果仿制药要进入美国市场,必须提交ANDA,ANDA申请人应按照相关的法律法规递交充分的科学论证,才能有助于加快审批流程。结论我国制药行业应抓住国际化的重要机遇,正确理解FDA先进科学的药品管理体系,同时完善我国仿制药注册审评制度,实现更多仿制药在美国等发达国家市场的上市。
OBJECTIVE To provide references for domestic generics going into the US market.METHODS The literature analysis,illustration and other research methods were used in this study to study the aspects including the framework of legislation,review process of generics,requirements on technical contents and common deficiencies during the ANDA(Abbreviate New Drug Application)review in the United States(US).RESULTS A generic drug must submit the ANDA application to obtain approval before entering the US market,a ANDA applicant should submit sufficient and reliable demonstrations to accelerate the approval process.CONCLUSION The domestic pharmaceutical industry should seize the opportunity of internationalization,correctly understand the advanced and sound drug management system of FDA,as well as improve the generic approval system,to help more and more generic enter the US market.

关键词(KeyWords)： 美国食品药品管理局;仿制药;审核过程;生物等效
FDA;generic drug;review process;bioequivalence

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 麦丽谊,陈昕,安金蒙,蒋杰
MAI Liyi,CHEN Xin,AN Jinmeng,JIANG Jie

参考文献(References)：

• [1]国家食品药品监督管理总局.国务院办公厅关于开展仿制药质量和疗效一致性评价的意见,国办发[2016]8号.[EB/OL].(2016-03-05)[2017-04-25].http://www.sda.gov.cn/WS01/CL0056/146200.html.
• [2]U.S FDA.Types of Applications[EB/OL].(2014-10-23)[2017-04-25].https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/default.htm.
• [3]U.S FDA.Orange Book Preface.[EB/OL].(2017-01-24)[2017-04-25].https://www.fda.gov/drugs/developmentapprovalprocess/ucm079068.htm.
• [4]U.S FDA.Frequently Asked Questions on Patents and Exclusivity[EB/OL].(2016-12-05)[2017-04-25].http://www.fda.gov/drugs/developmentapprovalprocess/ucm079031.htm.
• [5]林淘曦,余娜,黄璐.美国首仿药制度及专利挑战策略研究[J].中国新药杂志.2016,25(19):2168-2173.
• [6]赵曦.原研药与仿制药的较量——美国Hatch-Waxman法案简介[J].中国发明与专利.2009(10):80-81.
• [7]熊兴龙,宋民宪,李婷.药品注册审批中的专利问题研究[J].中国药房.2014,25(5):395-397.
• [8]余煊强,张清,阮文兴.美国FDA仿制药的法规及审批程序[J].中国处方药.2008,9(78):50-52.
• [9]U.S FDA.Generic Drug User Fee Act(GDUFA)[EB/OL].(2012-04-13)[2017-04-25].http://www.fda.gov/For Industry/User Fees/Generic Drug User Fees/default.htm.
• [10]U.S FDA.Office of Generic Drugs(OGD)Annual Report for 2016[EB/OL].(2017-03-01)[2017-04-25].http://www.fda.gov/.../approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm542710.htm.
• [11]U.S FDA.SUPAC-MR:Modified Release Solid Oral Dosage Forms Scale-Up and Post approval Changes:Chemistry,Manufacturing,and Controls;In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation[EB/OL].(1997-06-10)[2017-04-25].https://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatory Information/Guidances/UCM070640.pdf.
• [12]U.S FDA.SUPAC-IR:Immediate-Release Solid Oral Dosage Forms:Scale-Up and Post-Approval Changes:Chemistry,Manufacturing and Controls,In Vitro Dissolution Testing,and In Vivo Bioequivalence Documentation[EB/OL].(1995-01-10)[2017-04-25].https://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatory Information/Guidances/UCM070636.pdf.
• [13]U.S FDA.FDA Guidance for Industry:Size,Shape,and Other Physical Attributes of Generic Tablets and Capsules Guidance for Industry[EB/OL].(2015-06-18)[2017-04-25].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377938.pdf.
• [14]U.S FDA.FDA Guidance for Industry:Pharmaceutical Solid Polymorphism[EB/OL].(2007-07-07)[2017-04-25].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072866.pdf.
• [15]U.S FDA.Orange Book Preface.[EB/OL].(2017-01-24)[2017-04-25].http://www.fda.gov/drugs/developmentapprovalprocess/ucm079068.htm.
• [16]U.S FDA.Guidance for Industry ANDA Submissions-Content and Format of Abbreviated New Drug Applications[EB/OL].(2014-06-13)[2017-04-25].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm400630.pdf.
• [17]U.S FDA.ANDA Filing Checklist[EB/OL].[2017-04-25].http://www.fda.gov/.../approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm320405.pdf.
• [18]U.S FDA.CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.10.Chemistry Review of Question-based Review(QbR)Submissions[EB/OL].(2014-11-12)[2017-04-25].https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/manualofpoliciesprocedures/ucm423752.pdf.
• [19]雷继峰,杨建红.美国仿制药审评审批制度的经验分析与研究[J].中国新药杂志.2016,25(19):2240-2249.
• [20]U.S FDA.DA Guidance for Industry,Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients[EB/OL].(2005-05-25)[2017-04-25].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079250.pdf.
• [21]U.S FDA.Technical Rejection Criteria for Study Data[EB/OL].(2017-03-02)[2017-04-25].www.fda.gov/.../formssubmissionrequirements/electronicsubmissions/ucm523539.pdf.
• [22]U.S FDA.FDA Guidance for Industry,ANDA Submissions-Refuseto Receive Standards[EB/OL].(2016-12-05)[2017-04-25].https://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatory Information/Guidances/UCM370352.pdf.
• [23]U.S FDA.Inactive Ingredients Database Download[EB/OL].(2017-01-18)[2017-04-25].http://www.fda.gov/drugs/informationondrugs/ucm113978.htm.
• [24]U.S FDA.CFR-Code of Federal Regulations Title 21,Sec.73.1200 Synthetic iron oxide[EB/OL].(2016-04-01)[2017-04-25].http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.1200.
• [25]U.S FDA.CFR-Code of Federal Regulations Title 21,Sec.314.94Content and format of an abbreviated application[EB/OL].(2016-04-01)[2017-04-25].http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.94.
• [26]ICH.Stability Testing of New Drug Substance and Products Q1A(R2)[EB/OL].(2003-02-06)[2017-04-25].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2_Guideline.pdf.
• [27]U.S FDA.ANDA Submissions-Refuse to Receive for Lack of Justification of Impurity Limits,Guidance for Industry[EB/OL].(2016-08-01)[2017-04-25].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm414598.pdf.
• [28]U.S FDA.FDA Guidance for Industry,Tablet Scoring:Nomenclature,Labeling,and Data for Evaluation[EB/OL].(2013-03-26)[2017-04-25].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM269921.pdf.
• [29]U.S FDA.Size,Shape,and Other Physical Attributes of Generic Tablets and Capsules,Guidance for Industry[EB/OL].(2015-06-07)[2017-04-25].https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377938.pdf.
• [30]U.S FDA.FDA Guidance for Industry,Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System[EB/OL].(2015-05-05)[2017-04-25].https://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatory Information/Guidances/UCM070246.pdf.
• [31]U.S FDA.Product-Specific Guidances for Generic Drug Development[EB/OL].(2016-12-01)[2017-04-25].https://www.fda.gov/Drugs/Guidance ComplianceRegulatory Information/Guidances/ucm075207.htm.